Close Menu

macular degeneration

NEW YORK (GenomeWeb) – AMD Insight today announced it has exclusively licensed from ArcticDx the commercial rights in Canada for the Macula Risk PGx test.

NEW YORK (GenomeWeb News) – Nicox, a company specializing in ophthalmic therapies and diagnostics, will market Sequenom's RetnaGene AMD test in North America, the partners said today.

Investigators from the Scripps Research Institute have published new preclinical data indicating that inhibiting microRNA-132 in the eye can prevent the neovascularization associated with wet age-related macular degeneration and similar eye conditions.

NEW YORK (GenomeWeb News) – A trio of studies published online yesterday in Nature Genetics are revealing new, rare risk loci for age-related macular degeneration.

RXi Pharmaceuticals this week released data from a phase I trial of its dermal anti-scarring drug RXI-109, showing that the compound was safe and well-tolerated.

This story has been updated to include comment from RXi's management.

Researchers from the Washington University School of Medicine this week published a report suggesting that a microRNA — miR-33 — could play a key role in the buildup of cholesterol in macrophages that is associated with age-related macular degeneration and may serve as a therapeu

NEW YORK (GenomeWeb News) – A meta-analysis of genome-wide association studies has uncovered seven new loci linked to increased risk of age-related macular degeneration, the AMD Gene Consortium reported in Nature Genetics yesterday.

NEW YORK (GenomeWeb News) – Sequenom and ArcticDx have settled their IP dispute, Sequenom disclosed in its Form 10-Q filed on Thursday.

Pages

23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.

China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.

In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.

NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.